Category: News

Spear Bio’s SPEAR UltraDetect™ BD-pTau 217 Assay Named a 2026 R&D 100 Award Winner

Prestigious R&D 100 Award recognizes Spear Bio’s innovation in ultra-sensitive measurement of brain-derived pTau 217 in plasma WOBURN, Mass.–(BUSINESS WIRE)– Spear Bio, a biotechnology company pioneering wash-free ultrasensitive immunoassay technology, today announced that its SPEAR UltraDetect™ BD-pTau 217 Assay has received a 2026 R&D 100 Award. Presented annually by R&D World, the awards recognize 100 of […]

Read More

Spear Bio to Unveil Novel Alzheimer’s Disease Immunoassays and Fully Automated Instrument Platform at AAIC 2026

Launches include the first commercially available singleplex eMTBR-Tau immunoassay, a novel pTau 217 assay for venous and capillary blood, and a fully automated instrument platform WOBURN, Mass.–(BUSINESS WIRE)–Spear Bio, an innovator in ultrasensitive protein biomarker detection, today announced plans to unveil new SPEAR immunoassay and instrument innovations at the Alzheimer’s Association International Conference® 2026, taking […]

Read More

Spear Bio Introduces New Ultra-Sensitive Neurodegenerative Assays and Expands Direct Access at AD/PD 2026

WOBURN, Mass.–(BUSINESS WIRE)–Spear Bio, an innovator in ultrasensitive protein biomarker detection, showcased three new SPEAR UltraDetect™ immunoassays—brain-derived p-Tau 217 (BD-pTau 217), α-synuclein (α-syn) and phospho-Ser129-α-synuclein (pS129-α-syn)—at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD 2026) last week. The product debuts coincide with the company’s newly established direct-to-customer operations in North America and Europe, an important step that will […]

Read More

Formulatrix® and Spear Bio Advance Automated Ultrasensitive Protein Detection Through Ongoing Partnership

Bedford, MA, January 15, 2026 — Formulatrix, a leader in laboratory automation solutions, and Spear Bio, an innovator in ultrasensitive protein biomarker detection, today announced their ongoing partnership to automate and optimize the SPEAR UltraDetect™ assay platform using the F.A.S.T.™ (Flow Axial Seal Tip) Liquid Handler. This partnership combines Spear Bio’s next-generation immunoassay technology with Formulatrix’s […]

Read More

Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership with Spear Bio for the Transformative Bio-Hermes-002 Study

Spear Bio joins collaborative study focused on new biomarkers designed to improve diagnosis of Alzheimer’s disease and dementias WASHINGTON, Jan. 12, 2026 (GLOBE NEWSWIRE) — The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Spear Bio, a biotechnology company pioneering wash-free ultrasensitive immunoassay technology, to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform […]

Read More

Spear Bio Launches Next Generation Ultrasensitive Immunoassay Solution SPEAR UltraDetect™ to Transform Neurodegenerative Disease Research  

Woburn, MA – July 25, 2025 – Spear Bio, a biotechnology company pioneering homogeneous ultrasensitive immunoassay technology, today announced the commercial launch of its SPEAR UltraDetect™ immunoassay solution. It delivers unparalleled sensitivity, specificity, precision, and scalability for robust biomarker measurement. The initial launch includes four assays, targeting key neurology biomarkers: phosphorylated tau 231 (pTau231), phosphorylated […]

Read More

Spear Bio Announces Strategic Partnership with Bio-Techne to accelerate the deployment of its next-generation immunoassay technology

Woburn, MA July 15, 2025 – Spear Bio, a biotechnology company pioneering homogeneous ultrasensitive immunoassay technology, is pleased to announce a strategic distribution partnership with Bio-Techne Corporation (NASDAQ: TECH), a global leading provider of innovative reagents, instruments, and solutions for life-science research and clinical diagnostics. The partnership significantly expands global access to Spear Bio’s groundbreaking […]

Read More

Spear Bio Secures FDA Breakthrough Device Designation for its novel pTau 217 Blood Test, Advancing Scalable Solutions for Early Alzheimer’s Disease Diagnosis

Woburn, MA – January 13, 2025 – Spear Bio Inc., a biotechnology company pioneering next-generation ultra-sensitive immunoassays, today announced that its pTau 217 blood test has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). This recognizes the test’s potential to address a critical unmet need for the millions of Americans […]

Read More

Spear Bio Secures $45 Million in Oversubscribed Series A Financing to Accelerate Product Launch for Protein Research and Disease Diagnostics

July 29, 2024 07:00 AM Eastern Daylight Time WOBURN, Mass.–(BUSINESS WIRE)–Spear Bio Inc., a biotechnology company enabling the measurement of protein molecules down to dozens of copies with ubiquitous qPCR equipment, announced the successful closing of its $45 million Series A financing. The oversubscribed round was co-led by Foresite Capital and Bio-Techne Corporation, with additional […]

Read More

Spear Bio, Developer of the Next-generation Ultrasensitive Immunodiagnostics and Proteomics Platform, Completes Raise of Tens of Millions of US Dollars With Oversubscribed Seed Prime

WOBURN, Mass., Nov. 29, 2023 /PRNewswire/ — Spear Bio Inc., a Harvard University biotech spin-off developing scalable solutions for ultrasensitive detection of protein biomarkers announced the completion of a raise of tens of millions of US dollars with its Seed Prime.

Read More